0001493152-17-012739.txt : 20171113 0001493152-17-012739.hdr.sgml : 20171110 20171109194221 ACCESSION NUMBER: 0001493152-17-012739 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 33 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171113 DATE AS OF CHANGE: 20171109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EnzymeBioSystems CENTRAL INDEX KEY: 0001471968 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270464302 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53854 FILM NUMBER: 171192456 BUSINESS ADDRESS: STREET 1: 8440 W. LAKE MEAD STREET 2: SUITE 214 CITY: LAS VEGAS STATE: NV ZIP: 89128 BUSINESS PHONE: 702-907-0615 MAIL ADDRESS: STREET 1: 8440 W. LAKE MEAD STREET 2: SUITE 214 CITY: LAS VEGAS STATE: NV ZIP: 89128 FORMER COMPANY: FORMER CONFORMED NAME: Enzyme Bio Systems DATE OF NAME CHANGE: 20090909 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

X	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2017

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to

Commission File Number: 000-53854

EnzymeBioSystems

(Exact name of registrant as specified in its charter)

Nevada		27-0464302
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

8440 W. Lake Mead, Suite 214, Las Vegas, NV		89128
(Address of principal executive offices)		(Zip Code)

(702) 907-0615
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [ ] No [ ] Not Applicable

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company, defined in Rule 12b-2 of the Exchange Act (Check one).

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ]		Smaller Reporting Company [X]
(Do not check if a smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

There were 2,609,510 shares of Common Stock outstanding and issuable as of October 31, 2017.

Table of Contents

EnzymeBioSystems

Index to Form 10-Q

For the Quarterly Period Ended September 30, 2017

PART I	Financial Information	3

ITEM 1.	Financial Statements	3
	Unaudited Interim Balance Sheets as of September 30, 2017 and June 30, 2017	3
	Unaudited Condensed Interim Statements of Operations for the three months ended September 30, 2017 and September 30, 2016	4
	Unaudited Condensed Interim Statements of Cash Flows for the three months ended September 30, 2017 and September 30, 2016	5
	Notes to the Condensed Interim Financial Statements	6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	16

ITEM 4T.	Controls and Procedures	17

PART II	Other Information	20

ITEM 1.	Legal Proceedings	20

ITEM 1A.	Risk Factors	20

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

ITEM 3.	Defaults Upon Senior Securities	20

ITEM 4.	Submission of Matters to a Vote of Security Holders	21

ITEM 5..	Other Information	21

ITEM 6.	Exhibits	21

	SIGNATURES	22

Part I. Financial Information

Item 1. Financial Statements

EnzymeBioSystems

Condensed Interim Balance Sheets

	September 30, 2017 (Unaudited)			June 30, 2017 (Audited)
ASSETS
Current assets:
Cash and cash equivalents	$	213,259		$	41,249
Prepaid expense		6,000			3,000
Total current assets		219,259			44,249

TOTAL ASSETS	$	219,259		$	44,249

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	100		$	100
Accrued expenses		4,000			4,000
Total current liabilities		4,100			4,100

Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, 125,000 and 125,000 shares of Series A Preferred Stock issued and outstanding as of September 30, 2017 and June 30, 2017, respectively		125			125
Common stock, $0.001 par value, 195,000,000 shares authorized, 1,834,510 and 832,235 shares issued and outstanding as of September 30, 2017 and June 30, 2017, respectively		1,835			832
Additional paid-in capital		1,460,995			1,261,543
Accumulated deficit		(1,247,796	)		(1,222,351	)
Total stockholders’ equity		215,159			40,149
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	219,259		$	44,249

The accompanying notes are an integral part of these financial statements.

EnzymeBioSystems

Condensed Interim Statements of Operations

(Unaudited)

	For the three months ended Sept 30, 2017			For the three months ended Sept 30, 2016

Revenue	$	-		$	-

Operating expenses:
Officers’ compensation		16,500			18,000
Professional Fees		7,500			7,500
Other		1,845			2,002
Total operating expenses		25,845			27,502

Loss from operations		(25,845	)		(27,502	)

Other income - net
Restitution from former officer		400			-
Other income - net		400			-

Net (Loss)	$	(25,445	)	$	(20,699	)

Weighted average number of common shares outstanding - basic and diluted		963,633			832,235

Net loss per common share - basic and diluted	$	(0.03	)	$	(0.02	)

The accompanying notes are an integral part of these financial statements.

EnzymeBioSystems

Condensed Interim Statements of Cash Flows

(Unaudited)

	For the three months ended September 30, 2017			For the three months ended September 30, 2016

OPERATING ACTIVITIES
Net Loss	$	(25,445	)	$	(27,502	)
Changes in operating assets and liabilities
Prepaid expenses		(3,000	)		-
Accounts payable		-			-
Accrued expenses		-			-

Cash (used) by operating activities		(28,445	)		(27,502	)

FINANCING ACTIVITIES
Proceeds from sale of Units		200,455
Net cash provided by financing activities		200,455			-

NET INCREASE (DECREASE) IN CASH		172,010			(27,502	)
CASH - BEGINNING OF THE PERIOD		41,249			140,042
CASH - END OF THE PERIOD	$	213,259		$	112,540

SUPPLEMENTAL DISCLOSURES:
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

EnzymeBioSystems

Notes to the Condensed Interim Financial Statements

September 30, 2017

(Unaudited)

NOTE 1 - CONDENSED INTERIM FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2017 and for all periods presented have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2017 audited financial statements. The results of operations for the period ended September 30, 2017 are not necessarily indicative of the operating results for the full year.

Basis of Presentation

In the opinion of management, the accompanying balance sheets and related interim statements of operations and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Preparing financial statements requires management to make estimates and assumptions the affect the reported amounts of assets, liabilities, revenue and expenses. Actual results and outcomes may differ from management’s estimates and assumptions.

Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Form 10-K.

Reverse Stock Split

Effective October 19, 2017, the Company effected a 1-for-20 reverse stock split of its common stock (which reduced the issued and outstanding shares of common stock from 16,641,822 shares to 832,235 shares) and its Series A Preferred Stock (which reduced the issued and outstanding shares of Series A Preferred Stock from 2,500,000 shares to 125,000 shares). The accompanying financial statements retroactively reflect this reverse stock split.

EnzymeBioSystems

Notes to the Condensed Interim Financial Statements

September 30, 2017

(Unaudited)

NOTE 2 - GOING CONCERN

These condensed financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2017, the Company has not recognized any revenues and has accumulated operating losses of approximately $(1,247,796) since inception. The Company’s ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and its ability to achieve and maintain profitable operations. Management plans to raise equity capital to finance the operating and capital requirements of the Company. Amounts raised will be used to further development of the Company’s products, to provide financing for marketing and promotion, to secure property and equipment, and for other working capital purposes. While the Company is putting forth its best efforts to achieve the above plans, there is no assurance that any such activity will generate sufficient funds necessary to continue operations.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might arise from the outcome of this uncertainty.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue recognition

The Company will apply the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to September 30, 2017, the Company has not recognized any revenues.

Recent accounting pronouncements

Certain accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company. The impact on the Company’s financial position and results of operations from adoption of these standards is not expected to be material.

EnzymeBioSystems

Notes to the Condensed Interim Financial Statements

September 30, 2017

(Unaudited)

NOTE 4 - STOCKHOLDERS’ EQUITY

The Company is authorized to issue up to 5,000,000 shares of its $0.001 par value preferred stock and up to 195,000,000 shares of its $0.001 par value common stock.

The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock, are not redeemable, and cannot be converted into Common Shares unless it is approved by the Board of Directors and agreed upon by the Series A Preferred Shareholders. The shares of Series A Preferred stock have no dividend rights but have a liquidation preference for funds paid for the Series A Preferred Stock shares.

In September, 2017, the Company began conducting a Private Offering, with accredited investors to help fund the Company. The Company is offering up to 3,750,000 Common Units at a price of $0.20 per Unit. Each Unit consists of one share of post reverse stock split common stock, one Class A warrant exercisable at $0.30 per share of post reverse stock split common stock, one Class B warrant exercisable at $0.40 per share of post reverse stock split common stock and one Class C warrant exercisable at $0.60 per share of post reverse stock split common stock. The Offering provides that Berkeley Clinic, L.C. (holder of 1,500,000 shares of Common Stock and 2,500,000 shares of Series A Preferred Stock) will maintain the same 63.6% voting control of the Company that it held prior to the Offering. The offering and sale of the Units in this Offering are intended to be exempt from registration under the Act by virtue of Section 4(2) of the Act, and Rule 506. From September 6, 2017 to September 30, 2017, we sold a total of 1,002,275 Common Units to 8 investors at a price of $0.20 per Unit for gross proceeds of $200,455.

NOTE 5 - RELATED PARTY TRANSACTIONS

On September 17, 2017, the Company organized a Nevada corporation named LCNS as a subsidiary of the Company. On September 29, 2017, LCNS sold 2,000,000 restricted shares of LCNS common stock to T. J. Jesky (1,000,000 shares) and Mark DeStefano (1,000,000 shares) at a price of $.005 per share and $10,000 was deposited in LCNS’s attorney’s client trust account. Jesky and DeStefano are members of Berkeley Clinic, L.C. (see Note 4).

The officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.

EnzymeBioSystems

Notes to the Condensed Interim Financial Statements

September 30, 2017

(Unaudited)

Note 6 – Subsequent Events

In October 2017, we sold a total of 775,000 Common Units (see Note 4) to 6 investors at a price of $0.20 per Unit for gross proceeds of $155,000.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Item 2. - Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Information

This Quarterly Report on Form 10-Q contains forward-looking statements. When used in this Quarterly Report on Form 10-Q, the words “anticipate,” “believe,” “estimate,” “will,” “plan,” “seeks,” “intend,” and “expect” and similar expressions identify forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in any forward-looking statements are reasonable, these plans, intentions, or expectations may not be achieved. Our actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied, by the forward-looking statements contained in this Quarterly Report on Form 10-Q. Important factors that could cause actual results to differ materially from our forward-looking statements are set forth in this Quarterly Report on Form 10-Q All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this Quarterly Report on Form 10-Q. Except as required by federal securities laws, we are under no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Critical Accounting Policies

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2017.

Results of Operations

Overview of Current Operations

History and Organization

The Company was organized June 26, 2009 (Date of Inception) under the laws of the State of Nevada, as EnzymeBioSystems. On September 17, 2017, the Company incorporated LCNS in Nevada as a wholly owned subsidiary to conduct different business operations than the Company.

Our Business

EnzymeBioSystems researches specialty enzymes and enzyme related products. We utilize enzyme technologies to develop solutions for a broad range of applications within the specialty chemical industry. These markets are largely served by a small number of large, well-established businesses and research university centers. We plan to work collaboratively with those industrial companies to develop differentiated, high performance enzyme solutions for their target markets, and to leverage their well-developed distribution capabilities to better exploit commercial opportunities. Our enzyme technology will tie-in with development of new commercial biological active compounds. We hope we can develop specialty enzymes to eliminate the side effects and toxicity of the new commercially developed products.

Enzyme Industry

Enzymes can be categorized as “enzyme inhibitors” and “enzyme activators.” Enzyme inhibitors are molecules that bind to enzymes and decrease their activity. Since blocking an enzyme’s activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Enzyme activators are molecules that bind to enzymes and increase their activity. These molecules are often involved in the allosteric [defined as having to do with a protein with a structure that is altered reversibly by a small molecule so that its original function is modified] regulation of enzymes in the control of metabolism. Both enzyme inhibitors and enzyme activators are currently used by many pharmaceutical and biotechnology companies in research and development of new drug compounds.

Enzymes also can be used as pharmaceutical products. Enzymes as pharmaceuticals have two important features that distinguish them from all other types of pharmaceutical products. First, enzymes often bind and act on their targets with great affinity and specificity. Second, enzymes are catalytic and convert multiple target molecules to the desired products. These two features make for what are considered specialized enzymes that can accomplish therapeutic biochemistry in the body that small molecules cannot. These characteristics have resulted in the development of many enzyme drugs for a wide range of disorders, e.g. insulin and interferon.

Business Strategy

We foresee our two areas of business opportunity, that include: 1) buying raw materials to produce specialty enzymes in our lab facility and offer these products for sale to research facilities and pharmaceutical companies; and 2) become a specialty contract manufacture for research universities and pharmaceutical companies that utilize enzymes in their research programs.

We plan to deploy our enzyme technologies across diverse markets that represent commercial opportunities in helping us build visibility for EnzymeBioSystems. We plan to use enzyme technologies to develop commercial solutions for a broad range of applications within the specialty chemical industry.

We currently have only limited resources and capability to develop, manufacture, market, sell, or distribute specialty enzyme products on a commercial scale. We will determine which specialty enzyme products to pursue independently based on various criteria, including: investment required, estimated time to market, regulatory hurdles, infrastructure requirements, and industry-specific expertise necessary for successful commercialization. At any time, we may modify our strategy and pursue collaborations for the development and commercialization of some specialty enzyme products that we had intended to pursue independently. In order for us to commercialize more specialty enzyme products directly, we plan to establish or obtain through outsourcing arrangements additional capability to develop, manufacture, market, sell, and distribute such products.

Marketing Strategy

Through our future independent and collaborative research and development programs, we plan to develop commercial enzyme products across multiple markets. In addition, we plan to develop a pipeline of enzyme product candidates that we expect to launch independently and/or in collaboration with strategic partners.

Competition

Our competitors have substantially greater financial, technical, and marketing resources than we do and may succeed in developing products that would render our products obsolete or noncompetitive. In addition, many of these competitors have significantly greater experience than we do in their respective fields. Our ability to compete successfully will depend on our ability to develop proprietary products that reach the market in a timely manner and are technologically superior to, and/or are less expensive than, other products on the market. Current competitors or other companies may develop technologies and products that are more effective than ours. Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors. The existing approaches of our competitors or new approaches or technology developed by our competitors may be more effective than those developed by us.

Any enzyme products that we develop will compete in multiple, highly competitive markets. For example, Codexis, Maxygen, Inc., Evotec, and Xencor have alternative evolution technologies. Integrated Genomics Inc., Myriad Genetics, Inc., and ArQule, Inc. perform screening, sequencing, and/or bioinformatics services. Novozymes A/S, Verenium Corporation, Genencor International Inc. and MPBiomedicals are involved in development, overexpression, fermentation, and purification of enzymes. Many of these competitors have significantly greater financial and human resources than we do. We believe that the principal competitive factors in our market are access to genetic material, technological experience and expertise, and proprietary position.

Our Current Business Strategy

Management is evaluating an enzyme compound which it believes has a specific therapeutic value in fighting tumors, specifically breast tumors. Management has undertaken research to study its synthetic Amooranin compound, which the Company has developed in-house. Some studies of Amooranin have already been completed in rats. Further, research is required to study Amooranin in a different animal species.

Amooranin, a triterpene acid with a novel structure isolated from the stem bark of Amoora rohituka, a tropical tree growing wild in India. Recent studies showed that multiple breast cancer cell lines respond to Amooranin in growth suppression assays. Mechanistic studies suggest that Amooranin suppresses growth factor signaling, induces cell cycle arrest, and promotes apoptosis. Because the anti-neoplastic activity of the plant-derived compound of Amooranin is relatively weak.

Our Chief Scientific Officer developed a new synthetic analogue of this molecule by chemical transformations in an attempt to identify a more potent agent. One of these analogues, Amooranin-Me, was found to inhibit proliferation of several breast cancer cells with greater potency than the parent compound of Amooranin. Preliminary screening of Amooranin-Me in in-vitro experiments revealed some potenecy against breast cancer MCF-7 cells with concentrations down to the nanomolar range. All these studies indicate that Amooranin-Me is a promising drug with potential to be used for human breast cancer prevention.

The Company has moved further along with the process of evaluating an enzyme compound which they believe has specific therapeutic value in fighting tumors. In an effort to evaluate this compound, management has had a series of meetings with various contract research organizations to enlist their expertise in performing animal studies. The research will study the use of an antitumor natural product called amooranin. Specifically, the two areas of this study will include: 1) an exam of the in vitro cytotoxicity of amooranin against hepatocellular carcinoma cells, and 2) investigate the dose responsive antitumor actions of amooranin against chemically induced hepatic tumorgenesis in rats and dogs.

Management wants to continue its research with Amooranin that will lead to the filing of an Investigational New Drug Application (“IND”) with the U. S. Food and Drug Administration. It is still too early to determine if this project has any potential value for the Company, and there are no assurances that the Company will ever be able to obtain an IND for this compound.

As of the date of this report, management of the Company has identified an independent chemical laboratory that can produce sufficient quantities of amooranin to proceed with the required animal studies. A small preclinical batch of methyl amooranin has been manufactured by the independent chemical laboratory. This preclinical batch is not large enough to sufficiently test in several animal studies needed to obtain an IND.

Patent, Trademark, License and Franchise Restrictions and Contractual Obligations and Concessions

We do not have any trademarks. In 2012, the two founders of the Company, along with a third party, as inventors, filed Patent Application # 14/369339 entitled “Amooranin Compounds and Analogs Thereof and Related Methods of Use.” The U.S. Patent Office informed us that they published the aforementioned pending Patent on December 4, 2014 (Publication No. 2014-0357711A1).

On September 28, 2017, we received a Notice of Allowance from the U.S. Patent Office that they approved the Company’s Patent Application #14/369339. A Notice of Allowance is issued by the United States Patent & Trademark Office to indicate that it believes an invention qualifies for a patent. The patent is not fully protected until it completes the final patent process and pays the appropriate fees. We are currently in the process of paying the final patent fees. As added disclosure, an invention is still considered “patent pending” until the final patent has been issued.

We plan to rely on trade secrets, technical know-how, and continuing invention to develop and maintain our competitive position. We will take security measures to protect our trade secrets, proprietary know-how and technologies, and confidential data and continue to explore further methods of protection. Our policy is to execute confidentiality agreements with our employees and consultants upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property.

Results of Operations for the three months ended September 30, 2017

During the three month period ended September 30, 2017, the Company did not generate any revenues. In addition, the Company does not expect to generate any profit for the next twelve months.

For the three months ending September 30, 2017, we experienced a net loss of $(25,445) or $(0.03) per share as compared to a net loss of $(20,699) or $(0.02) per share for the same period last year. The net loss for the three months ending September 30, 2017 was attributed to $16,500 in officers’ compensation, $7,500 in audit fees, and $1,845 in other general and administrative expense.

Revenues

The Company has generated no revenues since its inception. As of September 30, 2017, the Company had an accumulated deficit of $(1,247,796). There can be no assurances that the Company can achieve or sustain profitability or that the Company’s operating losses will not increase in the future.

Going Concern

Our independent auditors included an explanatory paragraph in their report on the June 30, 2017 audited financial statements regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors. Our ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and our ability to achieve and maintain profitable operations.

Therefore, management plans to raise equity capital to finance the operating and capital requirements of the Company. While the Company is devoting its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds that will be available for operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Plan of Operation

Management does not believe that the Company will be able to generate any significant profit during the coming year. Management believes developmental costs will most likely exceed its cash reserves for the coming year. Management is evaluating an enzyme compound, specifically a synthetic Amooranin which it believes has a specific therapeutic value in fighting tumors. Therefore, management will be required to seek outside funding, of at least $500,000.

Future funding could result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities and/or amortization expenses related to goodwill and other intangible assets, which could materially adversely affect the Company’s business, results of operations and financial condition. Any future acquisitions of other businesses, technologies, services or product(s) might require the Company to obtain additional equity or debt financing, which might not be available on terms favorable to the Company, or at all, and such financing, if available, might be dilutive.

Management hopes its research will identify an enzyme compound developed by the Company that will lead to the filing of an Investigational New Drug Application with the U. S. Food and Drug Administration. It is still too early to determine if this project has any potential value for the Company, and there are no assurances that the Company will ever be able to obtain an IND for this compound.

Summary of any product research and development that we will perform for the term of our plan of operation.

We plan to deploy our enzyme technologies across diverse markets that represent commercial opportunities in helping us build visibility for EnzymeBioSystems. We believe that this market approach might give us the ability to broadly apply our enzyme development and manufacturing capabilities while minimizing commercial risk in that research or pharmaceutical companies might change their needs during our development processes.

Expected purchase or sale of plant and significant equipment.

We have not purchased or sold any plant or significant equipment.

Significant changes in the number of employees.

As of September 30, 2017, we did not have any employees. We are dependent upon our two officers for our future business development. As our operations expand we anticipate the need to hire additional employees, consultants and professionals; however, the exact number is not quantifiable at this time.

Liquidity and Capital Resources

The Company is authorized to issue 195,000,000 shares of its $0.001 par value common stock and 5,000,000 shares of its $0.001 par value preferred stock. As of September 30, 2017, the Company has 1,834,510 shares of common stock issued and outstanding and 125,000 of its Series A Preferred Shares issued and outstanding. The numbers have been adjusted for a 1-for-20 reverse stock split that took place on October 19, 2017. As of September 30, 2017, the Company had current assets of $219,259 and current liabilities of $4,100.

The Company has limited financial resources available, which has had an adverse impact on the Company’s liquidity, activities and operations. In order for the Company to remain a Going Concern it will need to find additional capital or generate revenues. Additional working capital may be sought through additional debt or equity private placements, additional notes payable to banks or related parties (officers, directors or stockholders), or from other available funding sources at market rates of interest, or a combination of these. The ability to raise necessary financing will depend on many factors, including the nature and prospects of any business to be acquired and the economic and market conditions prevailing at the time financing is sought. No assurances can be given that any necessary financing can be obtained on terms favorable to the Company, or at all.

EnzymeBioSystems’s Funding Requirements

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Estimates

Revenue Recognition: We will recognize revenue from product sales once all of the following criteria for revenue recognition have been met: pervasive evidence that an agreement exists; the services have been rendered; the fee is fixed and determinable and not subject to refund or adjustment; and collection of the amount due is reasonable assured.

New Accounting Standards

The Company’s management has evaluated all the recently issued accounting pronouncements through the filing date of these financial statements and does not believe that any of these pronouncements will have a material impact on the Company’s financial position and results of operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable.

Item 4T. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC, and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Interim Accounting Officer, to allow timely decisions regarding required disclosures.

Management has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on such evaluation, management concluded that, our disclosure controls and procedures were not effective. Our disclosure controls and procedures were not effective because of the “material weaknesses” described below under “Management’s report on internal control over financial reporting,” which are in the process of being remediated as described below under “Management Plan to Remediate Material Weaknesses.”

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in rules promulgated under the Exchange Act, is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and affected by our Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:

	●	pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

	●	provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our Board of Directors; and

	●	provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable, not absolute, assurance that the objectives of the control system are met and may not prevent or detect misstatements. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting.

However, these inherent limitations are known features of the financial reporting process, and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Further, over time control may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of June 30, 2017. In making its assessment, management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on its assessment, management has concluded that we had certain control deficiencies described below that constituted material weaknesses in our internal controls over financial reporting. As a result, our internal control over financial reporting was not effective as of June 30, 2017.

A “material weakness” is defined under SEC rules as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls. As a result of management’s review of the investigation issues and results, and other internal reviews and evaluations that were completed after the end of the year related to the preparation of management’s report on internal controls over financial reporting required for this annual report on Form 10-K, management concluded that we had material weaknesses in our control environment and financial reporting process which consisted of the following:

Deficiencies Related to the Design and Operation of Certain Company-Level Controls

	●	Non-compliance by the former chief financial officer with regards to unauthorized travel and entertainment expenses;

	●	Unauthorized personal charges by the former chief financial officer.

Deficiencies Related to the Design and Operation of Certain Accounting Procedures

	●	Inadequate accounting procedures responsible for processing payment requests by our former chief financial officer related to travel and entertainment expenditures

	●	Lack of clear procedures for ensuring appropriate expense controls.

In consultation with our board of directors and new interim accounting officer, we are implementing certain remediation measures, and we are in the process of creating and implementing additional remediation plans for the internal control deficiencies noted above. The remediation activities include:

Design and Operation of Certain Company-Level Controls

Management has conducted an internal investigation relating to the unauthorized travel and entertainment expenses, incurred by the former chief financial officer. We have identified various expenses by the Company’s former chief financial officer since February, 2015 that were inconsistent with Company policies or that lacked sufficient documentation. On September 21, 2015, the former chief financial officer was dismissed for cause, based on a breach of his fiduciary duties. The Board has subsequently appointed a new interim accounting officer and corporate secretary

We will implement a check-and-balance system to monitor all expenses.

Design and Operation of Certain Accounting Procedures

We expect to complete the following remediation during the remainder of 2017.

We will adopt a new policy and procedure that authorizes and reviews the accounting oversight by persons at the appropriate levels within the Company.

Changes in Internal Controls over Financial Reporting

On September 21, 2015, we replaced our former chief financial officer. We added a new interim accounting officer who has experience related to the application of generally accepted accounting principles and U.S. Securities and Exchange Commission rules and regulations as they pertain to financial reporting. We believe these personnel changes will strengthen our controls related to financial reporting. Other than these changes, there have been no other changes to our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Item 1 — Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

In November 2015, the Company filed a complaint titled EnzymeBioSystems v. Edward C. Zimmerman III, Case No. A-15-727138-CV, filed in the District Court of the State of Nevada for Clark County. EnzymeBioSystems, the plaintiff in this matter, brings an action against Edward C. Zimmerman III, the defendant, for reimbursement of $38,567.95 in unauthorized expenditures. On July 24, 2017, Mr. Zimmerman was discharged from any debt owed to the Company via Chapter 7 Bankruptcy in the United States Bankruptcy Court, District of Nevada. As such, the Company cannot collect from Zimmerman in the state court action.

On January 26, 2017, Edward C. Zimmerman III entered into a Guilty Plea Agreement, in Nevada District Court, Case Number C-16-319713-1, using an Alford plea to attempted theft. He was ordered to pay restitution to the Company of $25,000 over the next three years. Through the date of this filing Mr. Zimmerman has sent the Company $400.00 in restitution. Mr. Zimmerman’s Chapter 7 Bankruptcy does not affect this Guilty Plea Agreement. He is still required to pay the $25,000 restitution to the Company over the next three years.

Item 1A - Risk Factors

See Risk Factors set forth in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 and the discussion in Item 1, above, under “ Liquidity and Capital Resources.”

Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds

The offering and sale of the Units in this Offering are intended to be exempt from registration under the Act by virtue of Section 4(2) of the Act, and Rule 506. In September, 2017, the Company raised $200,455, representing 1,002,275 Common Units.

Item 3 — Defaults Upon Senior Securities

None.

Item 4 — Submission of Matters to a Vote of Security Holders

None.

Item 5 — Other Information

None.

Item 6 — Exhibits

Exhibit Number	Ref	Description of Document
31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Principal Accounting Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EnzymeBioSystems Registrant

Date: November 9, 2017		/s/ Gary Rojewski
	Name:	Gary Rojewski
	Its:	Principal Executive Officer
Date: November 9, 2017		/s/ John Dean Harper
	Name:	John Dean Harper
	Its:	Interim Chief Accounting Officer

EX-31.1 2 ex31-1.htm

Exhibit 31.1 - SECTION 302 CERTIFICATION

EXHIBIT 31.1

Rule 13a-14(a)/15d-14(a) Certifications

I, Gary Rojewski, certify that:

(1)	I have reviewed this quarterly report on Form 10-Q of EnzymeBioSystems;

(2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Gary Rojewski
Gary Rojewski
Principal Executive Officer

Date: November 9, 2017

EX-31.2 3 ex31-2.htm

Exhibit 31.2 - SECTION 302 CERTIFICATION

EXHIBIT 31.2

Rule 13a-14(a)/15d-14(a) Certifications

I, John Dean Harper, certify that:

(1)	I have reviewed this quarterly report on Form 10-Q of EnzymeBioSystems;

(2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ John Dean Harper
John Dean Harper
Interim Chief Accounting Officer

Date: November 9, 2017

EX-32.1 4 ex32-1.htm

Exhibit 32.1 - SECTION 906 CERTIFICATION

EXHIBIT 32.1

Section 1350 Certifications

I am the Principal Executive Officer of EnzymeBioSystems, a Nevada corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter year ended September 30, 2017 and filed with the U.S. Securities and Exchange Commission (“Form 10-Q’).

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of EnzymeBioSystems (the “Company”) certifies to his knowledge that:

(1)	The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the Company.

/s/ Gary Rojewski
Gary Rojewski
Its: Principal Executive Officer

Date: November 8, 2017

EX-32.2 5 ex32-2.htm

Exhibit 32.2 - SECTION 906 CERTIFICATION

EXHIBIT 32.2

Section 1350 Certifications

I am the Principal Accounting Officer of EnzymeBioSystems, a Nevada corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter year ended September 30, 2017 and filed with the U.S. Securities and Exchange Commission (“Form 10-Q’).

(1)	The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the Company.

/s/ John Dean Harper
John Dean Harper
Its: Interim Chief Accounting Officer

Date: November 9, 2017

EX-101.INS 6 enzb-20170930.xml XBRL INSTANCE FILE 0001471968 2017-07-01 2017-09-30 0001471968 2017-10-31 0001471968 2017-06-30 0001471968 2016-06-30 0001471968 2017-09-30 0001471968 2016-07-01 2016-09-30 0001471968 us-gaap:SeriesAPreferredStockMember 2017-07-01 2017-09-30 0001471968 2016-09-30 0001471968 ENZB:OctoberNineteenTwoThousandAndSeventeenMember 2017-07-01 2017-09-30 0001471968 ENZB:OctoberNineteenTwoThousandAndSeventeenMember us-gaap:MinimumMember 2017-09-30 0001471968 ENZB:OctoberNineteenTwoThousandAndSeventeenMember us-gaap:MaximumMember 2017-09-30 0001471968 ENZB:OctoberNineteenTwoThousandAndSeventeenMember us-gaap:PreferredStockMember us-gaap:MinimumMember 2017-09-30 0001471968 ENZB:OctoberNineteenTwoThousandAndSeventeenMember us-gaap:PreferredStockMember us-gaap:MaximumMember 2017-09-30 0001471968 us-gaap:MaximumMember 2017-07-01 2017-09-30 0001471968 ENZB:PostReverseStockSplitMember ENZB:ClassAWarrantMember 2017-09-30 0001471968 ENZB:PostReverseStockSplitMember ENZB:ClassBWarrantMember 2017-09-30 0001471968 ENZB:PostReverseStockSplitMember ENZB:ClassCWarrantMember 2017-09-30 0001471968 us-gaap:CommonStockMember 2017-07-01 2017-09-30 0001471968 us-gaap:PreferredStockMember 2017-07-01 2017-09-30 0001471968 ENZB:EightInvestorsMember 2017-09-06 2017-09-30 0001471968 ENZB:EightInvestorsMember 2017-09-30 0001471968 ENZB:LCNSMember 2017-09-28 2017-09-29 0001471968 ENZB:JJeskyMember 2017-09-28 2017-09-29 0001471968 ENZB:MarkDeStefanoMember 2017-09-28 2017-09-29 0001471968 ENZB:LCNSMember 2017-09-29 0001471968 us-gaap:SubsequentEventMember 2017-10-18 2017-10-19 0001471968 us-gaap:SubsequentEventMember us-gaap:MinimumMember 2017-10-19 0001471968 us-gaap:SubsequentEventMember us-gaap:MaximumMember 2017-10-19 0001471968 us-gaap:SubsequentEventMember us-gaap:MinimumMember us-gaap:PreferredStockMember 2017-10-19 0001471968 us-gaap:SubsequentEventMember us-gaap:MaximumMember us-gaap:PreferredStockMember 2017-10-19 0001471968 us-gaap:SubsequentEventMember ENZB:SixInvestorsMember 2017-10-01 2017-10-31 0001471968 us-gaap:SubsequentEventMember ENZB:SixInvestorsMember 2017-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure EnzymeBioSystems 0001471968 10-Q 2017-09-30 false --06-30 Smaller Reporting Company Q1 2018 2609510

41249

140042

213259

112540

3000

6000

44249

219259

44249

219259

100

4000

125

832

1835

1261543

1460995

-1222351

-1247796

40149

215159

44249

219259

0.001

5000000

125000

2500000

125000

2500000

125000

2500000

125000

2500000

195000000

832235

1834510

832235

16641822

832235

16641822

832235

1834510

832235

16641822

832235

16641822

16500

18000

7500

25845

27502

-25845

-27502

400

-25445

-20699

963633

832235

-0.03

-0.02

3000

-28445

-27502

172010

-27502

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES   Use of Estimates   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Revenue recognition   The Company will apply the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to September 30, 2017, the Company has not recognized any revenues.   Recent accounting pronouncements   Certain accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company. The impact on the Company’s financial position and results of operations from adoption of these standards is not expected to be material.

NOTE 2 - GOING CONCERN   These condensed financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2017, the Company has not recognized any revenues and has accumulated operating losses of approximately $(1,247,796) since inception. The Company’s ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and its ability to achieve and maintain profitable operations. Management plans to raise equity capital to finance the operating and capital requirements of the Company. Amounts raised will be used to further development of the Company’s products, to provide financing for marketing and promotion, to secure property and equipment, and for other working capital purposes. While the Company is putting forth its best efforts to achieve the above plans, there is no assurance that any such activity will generate sufficient funds necessary to continue operations.   These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might arise from the outcome of this uncertainty.

NOTE 4 - STOCKHOLDERS’ EQUITY   The Company is authorized to issue up to 5,000,000 shares of its $0.001 par value preferred stock and up to 195,000,000 shares of its $0.001 par value common stock.   The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock, are not redeemable, and cannot be converted into Common Shares unless it is approved by the Board of Directors and agreed upon by the Series A Preferred Shareholders. The shares of Series A Preferred stock have no dividend rights but have a liquidation preference for funds paid for the Series A Preferred Stock shares.   In September, 2017, the Company began conducting a Private Offering, with accredited investors to help fund the Company. The Company is offering up to 3,750,000 Common Units at a price of $0.20 per Unit. Each Unit consists of one share of post reverse stock split common stock, one Class A warrant exercisable at $0.30 per share of post reverse stock split common stock, one Class B warrant exercisable at $0.40 per share of post reverse stock split common stock and one Class C warrant exercisable at $0.60 per share of post reverse stock split common stock. The Offering provides that Berkeley Clinic, L.C. (holder of 1,500,000 shares of Common Stock and 2,500,000 shares of Series A Preferred Stock) will maintain the same 63.6% voting control of the Company that it held prior to the Offering. The offering and sale of the Units in this Offering are intended to be exempt from registration under the Act by virtue of Section 4(2) of the Act, and Rule 506. From September 6, 2017 to September 30, 2017, we sold a total of 1,002,275 Common Units to 8 investors at a price of $0.20 per Unit for gross proceeds of $200,455.

NOTE 5 - RELATED PARTY TRANSACTIONS   On September 17, 2017, the Company organized a Nevada corporation named LCNS as a subsidiary of the Company. On September 29, 2017, LCNS sold 2,000,000 restricted shares of LCNS common stock to T. J. Jesky (1,000,000 shares) and Mark DeStefano (1,000,000 shares) at a price of $.005 per share and $10,000 was deposited in LCNS’s attorney’s client trust account. Jesky and DeStefano are members of Berkeley Clinic, L.C. (see Note 4).   The officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.

Note 6 – Subsequent Events   Effective October 19, 2017, the Company effected a 1-for-20 reverse stock split of its common stock (which reduced the issued and outstanding shares of common stock from 16,641,822 shares to 832,235 shares) and its Series A Preferred Stock (which reduced the issued and outstanding shares of Series A Preferred Stock from 2,500,000 shares to 125,000 shares). The accompanying financial statements retroactively reflect this reverse stock split.   In October 2017, we sold a total of 775,000 Common Units (see Note 4) to 6 investors at a price of $0.20 per Unit for gross proceeds of $155,000.

Use of Estimates   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue recognition   The Company will apply the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to September 30, 2017, the Company has not recognized any revenues.

Recent accounting pronouncements   Certain accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company. The impact on the Company’s financial position and results of operations from adoption of these standards is not expected to be material.

ENZB

4100

1845

2002

400

200455

1-for-20 reverse stock split

1 for 20 reverse stock split

3750000

1500000

2500000

1002275

775000

0.20

0.005

0.20

0.30

0.40

0.60

2000000

1000000

10000

NOTE 1 - CONDENSED INTERIM FINANCIAL STATEMENTS   The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2017 and for all periods presented have been made.   Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2017 audited financial statements. The results of operations for the period ended September 30, 2017 are not necessarily indicative of the operating results for the full year.   Basis of Presentation   In the opinion of management, the accompanying balance sheets and related interim statements of operations and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Preparing financial statements requires management to make estimates and assumptions the affect the reported amounts of assets, liabilities, revenue and expenses. Actual results and outcomes may differ from management’s estimates and assumptions.   Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Form 10-K.   Reverse Stock Split   Effective October 19, 2017, the Company effected a 1-for-20 reverse stock split of its common stock (which reduced the issued and outstanding shares of common stock from 16,641,822 shares to 832,235 shares) and its Series A Preferred Stock (which reduced the issued and outstanding shares of Series A Preferred Stock from 2,500,000 shares to 125,000 shares). The accompanying financial statements retroactively reflect this reverse stock split.

The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock

0.636

200455

155000

EX-101.SCH 7 enzb-20170930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Interim Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Interim Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Interim Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Interim Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Condensed Interim Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Condensed Interim Financial Statements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 enzb-20170930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 enzb-20170930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 enzb-20170930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Report Date [Axis] October 19, 2017 [Member] Range [Axis] Minimum [Member] Maximum [Member] Equity Components [Axis] Series A Preferred Stock [Member] Scenario [Axis] Post Reverse Stock Split [Member] Class A Warrant [Member] Class B Warrant [Member] Class C Warrant [Member] Common Stock [Member] Title of Individual [Axis] Eight investors [Member] Legal Entity [Axis] LCNS [Member] Related Party [Axis] J. Jesky [Member] Mark DeStefano [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Six Investors [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Prepaid expense Total current assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses Total current liabilities Stockholders’ equity: Preferred stock, $0.001 par value, 5,000,000 shares authorized, 125,000 and 125,000 shares of Series A Preferred Stock issued and outstanding as of September 30, 2017 and June 30, 2017, respectively Common stock, $0.001 par value, 195,000,000 shares authorized, 1,834,510 and 832,235 shares issued and outstanding as of September 30, 2017 and June 30, 2017, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Preferred stock, par value Preferred stock, shares authorized Series A Preferred stock, shares issued Series A Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: Officers’ compensation Professional Fees Other Total operating expenses Loss from operations Other income - net Restitution from former officer Other income - net Net (Loss) Weighted average number of common shares outstanding - basic and diluted Net loss per common share - basic and diluted Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net Loss Changes in operating assets and liabilities Prepaid expenses Accounts payable Accrued expenses Cash (used) by operating activities FINANCING ACTIVITIES Proceeds from sale of Units Net cash provided by financing activities NET INCREASE (DECREASE) IN CASH CASH - BEGINNING OF THE PERIOD CASH - END OF THE PERIOD SUPPLEMENTAL DISCLOSURES: Interest paid Income taxes paid Organization, Consolidation and Presentation of Financial Statements [Abstract] Condensed Interim Financial Statements Going Concern Accounting Policies [Abstract] Summary of Significant Accounting Policies Equity [Abstract] Stockholders' Equity Related Party Transactions [Abstract] Related Party Transactions Subsequent Events [Abstract] Subsequent Events Use of Estimates Revenue Recognition Recent Accounting Pronouncements Statement [Table] Statement [Line Items] Reverse stock split Preferred stock, shares issued Preferred stock, shares outstanding Preferred shares voting rights Offering of common stock units Shares issued, price per share Exercise price of warrants Voting control percentage Gross proceeds Stock issued during period, share, restricted stock award, gross Stock issued during period, value, restricted stock award, gross Number of shares issued Shares issued price per share Number of shares issued value Shareholder Acquisition Corp [Member] Berkeley Clinic, LC [Member] July 7, 2017 and September 8, 2017 [Member] Restitution from former officer. October 19, 2017 [Member] Post Reverse Stock Split [Member] Class A Warrant [Member] Class B Warrant [Member] Class C Warrant [Member] 8 investors [Member] LCNS [Member] J. Jesky [Member] Mark DeStefano [Member] 6 investors [Member] Voting control percentage. Preferred Stock [Member] Assets, Current Assets Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Other Nonoperating Income (Expense) Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) EX-101.PRE 11 enzb-20170930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Oct. 31, 2017
Document And Entity Information
Entity Registrant Name	EnzymeBioSystems
Entity Central Index Key	0001471968
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,609,510
Trading Symbol	ENZB
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Interim Balance Sheets - USD ($)	Sep. 30, 2017	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 213,259	$ 41,249
Prepaid expense	6,000	3,000
Total current assets	219,259	44,249
TOTAL ASSETS	219,259	44,249
Current liabilities:
Accounts payable	100	100
Accrued expenses	4,000	4,000
Total current liabilities	4,100	4,100
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, 125,000 and 125,000 shares of Series A Preferred Stock issued and outstanding as of September 30, 2017 and June 30, 2017, respectively	125	125
Common stock, $0.001 par value, 195,000,000 shares authorized, 1,834,510 and 832,235 shares issued and outstanding as of September 30, 2017 and June 30, 2017, respectively	1,835	832
Additional paid-in capital	1,460,995	1,261,543
Accumulated deficit	(1,247,796)	(1,222,351)
Total stockholders’ equity	215,159	40,149
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 219,259	$ 44,249

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Interim Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Jun. 30, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Series A Preferred stock, shares issued	125,000	125,000
Series A Preferred stock, shares outstanding	125,000	125,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	195,000,000	195,000,000
Common stock, shares issued	1,834,510	832,235
Common stock, shares outstanding	1,834,510	832,235

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Interim Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenue
Operating expenses:
Officers’ compensation	16,500	18,000
Professional Fees	7,500	7,500
Other	1,845	2,002
Total operating expenses	25,845	27,502
Loss from operations	(25,845)	(27,502)
Other income - net
Restitution from former officer	400
Other income - net	400
Net (Loss)	$ (25,445)	$ (20,699)
Weighted average number of common shares outstanding - basic and diluted	963,633	832,235
Net loss per common share - basic and diluted	$ (0.03)	$ (0.02)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Interim Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
OPERATING ACTIVITIES
Net Loss	$ (25,445)	$ (20,699)
Changes in operating assets and liabilities
Prepaid expenses	(3,000)
Accounts payable
Accrued expenses
Cash (used) by operating activities	(28,445)	(27,502)
FINANCING ACTIVITIES
Proceeds from sale of Units	200,455
Net cash provided by financing activities	200,455
NET INCREASE (DECREASE) IN CASH	172,010	(27,502)
CASH - BEGINNING OF THE PERIOD	41,249	140,042
CASH - END OF THE PERIOD	213,259	112,540
SUPPLEMENTAL DISCLOSURES:
Interest paid
Income taxes paid

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Interim Financial Statements

3 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Interim Financial Statements

NOTE 1 - CONDENSED INTERIM FINANCIAL STATEMENTS

Basis of Presentation

Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Form 10-K.

Reverse Stock Split

XML 18 R7.htm IDEA: XBRL DOCUMENT

Going Concern

3 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

NOTE 2 - GOING CONCERN

XML 19 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

3 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Revenue recognition

Recent accounting pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Sep. 30, 2017

Equity [Abstract]

Stockholders' Equity

NOTE 4 - STOCKHOLDERS’ EQUITY

The Company is authorized to issue up to 5,000,000 shares of its $0.001 par value preferred stock and up to 195,000,000 shares of its $0.001 par value common stock.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Sep. 30, 2017

Related Party Transactions

NOTE 5 - RELATED PARTY TRANSACTIONS

XML 22 R11.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

Note 6 – Subsequent Events

In October 2017, we sold a total of 775,000 Common Units (see Note 4) to 6 investors at a price of $0.20 per Unit for gross proceeds of $155,000.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Revenue recognition The Company will apply the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to September 30, 2017, the Company has not recognized any revenues.
Recent Accounting Pronouncements	Recent accounting pronouncements Certain accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company. The impact on the Company’s financial position and results of operations from adoption of these standards is not expected to be material.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Condensed Interim Financial Statements (Details Narrative) - shares	3 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Common stock, shares issued	1,834,510	832,235
Common stock, shares outstanding	1,834,510	832,235
Preferred stock, shares issued	125,000	125,000
Preferred stock, shares outstanding	125,000	125,000
October 19, 2017 [Member]
Reverse stock split	1-for-20 reverse stock split
October 19, 2017 [Member] \| Minimum [Member]
Common stock, shares issued	832,235
Common stock, shares outstanding	832,235
October 19, 2017 [Member] \| Minimum [Member] \| Series A Preferred Stock [Member]
Preferred stock, shares issued	125,000
Preferred stock, shares outstanding	125,000
October 19, 2017 [Member] \| Maximum [Member]
Common stock, shares issued	16,641,822
Common stock, shares outstanding	16,641,822
October 19, 2017 [Member] \| Maximum [Member] \| Series A Preferred Stock [Member]
Preferred stock, shares issued	2,500,000
Preferred stock, shares outstanding	2,500,000

XML 25 R14.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2017	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (1,247,796)	$ (1,222,351)

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2017	Jun. 30, 2017
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	195,000,000	195,000,000	195,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Shares issued, price per share	$ 0.20	$ 0.20
Voting control percentage	63.60%	63.60%
Eight investors [Member]
Offering of common stock units	1,002,275
Shares issued, price per share	$ 0.20	$ 0.20
Gross proceeds	$ 200,455
Common Stock [Member]
Offering of common stock units		1,500,000
Series A Preferred Stock [Member]
Offering of common stock units		2,500,000
Post Reverse Stock Split [Member] \| Class A Warrant [Member]
Exercise price of warrants	$ 0.30	$ 0.30
Post Reverse Stock Split [Member] \| Class B Warrant [Member]
Exercise price of warrants	0.40	0.40
Post Reverse Stock Split [Member] \| Class C Warrant [Member]
Exercise price of warrants	$ 0.60	$ 0.60
Maximum [Member]
Offering of common stock units		3,750,000
Series A Preferred Stock [Member]
Preferred shares voting rights		The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock

XML 27 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	Sep. 29, 2017	Sep. 30, 2017
Shares issued, price per share		$ 0.20
J. Jesky [Member]
Stock issued during period, share, restricted stock award, gross	1,000,000
Mark DeStefano [Member]
Stock issued during period, share, restricted stock award, gross	1,000,000
LCNS [Member]
Stock issued during period, share, restricted stock award, gross	2,000,000
Shares issued, price per share	$ 0.005
Stock issued during period, value, restricted stock award, gross	$ 10,000

XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Oct. 19, 2017	Oct. 31, 2017	Sep. 30, 2017	Jun. 30, 2017
Common stock, shares issued			1,834,510	832,235
Common stock, shares outstanding			1,834,510	832,235
Preferred stock, shares issued			125,000	125,000
Preferred stock, shares outstanding			125,000	125,000
Shares issued price per share			$ 0.20
Series A Preferred Stock [Member]
Number of shares issued			2,500,000
Maximum [Member]
Number of shares issued			3,750,000
Subsequent Event [Member]
Reverse stock split	1 for 20 reverse stock split
Subsequent Event [Member] \| Six Investors [Member]
Number of shares issued		775,000
Shares issued price per share		$ 0.20
Number of shares issued value		$ 155,000
Subsequent Event [Member] \| Minimum [Member]
Common stock, shares issued	832,235
Common stock, shares outstanding	832,235
Subsequent Event [Member] \| Minimum [Member] \| Series A Preferred Stock [Member]
Preferred stock, shares issued	125,000
Preferred stock, shares outstanding	125,000
Subsequent Event [Member] \| Maximum [Member]
Common stock, shares issued	16,641,822
Common stock, shares outstanding	16,641,822
Subsequent Event [Member] \| Maximum [Member] \| Series A Preferred Stock [Member]
Preferred stock, shares issued	2,500,000
Preferred stock, shares outstanding	2,500,000

EXCEL 29 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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